|
|
|
| Efficacy Analysis of Dapagliflozin Combined with Metformin in the Treatment of Patients with Type 2 Diabetes |
| CHEN Xianle, ZHANG Chunhua |
| Department of Internal Medicine, Xinghai Hospital, Suzhou Industrial Park, Suzhou Jiangsu 215000 |
|
|
|
|
Abstract 【Objective】To investigate the clinical efficacy of dapagliflozin combined with metformin hydrochloride in the treatment of type 2 diabetes(T2DM). 【Methods】A total of 87 patients with type 2 diabetes treated in our hospital from September 2020 to September 2023 were selected and divided into the observation group(treated with dapagliflozin combined with metformin hydrochloride, n=44) and the control group(treated with metformin hydrochloride, n=43) by random number table method. Fasting blood glucose(FPG), 2 h postprandial blood glucose(2hPG) and glycosylated hemoglobin(HbA1c), blood glucose standard deviation(sDBG), mean blood glucose fluctuation range(MAGE), inflammatory factors [C-reactive protein(CRP), tumor necrosis factor-α(TNF-α), interleukin-6(IL-6), serum homocysteine(Hcy), cystatin C(cys C)], endocrine hormones [fasting insulin(Fins), pancreatic island β cell index(HOMA-β), insulin sensitivity index(HOMA-IR)], oxidative stress level [superoxide dismutase(SOD), catalase(CAT)] and incidence of adverse reactions were compared between the two groups before and after treatment. 【Results】Compared to before treatment, the levels of FPG, 2hPG, HbA1c, sDBG, MAGE, CRP, TNF-α, IL-6, Hcy and cys C in the two groups of T2DM patients decreased after treatment, while the above measurements in the observation group were significantly lower than those in the control group with statistical significance(P<0.05). Fins, SOD, CAT levels and HOMA-β of both groups increased after treatment if compared with before treatment, and their values in the observation group were significantly higher than those in the control group. The HOMA-IR of both groups decreased after treatment, and HOMA-IR level in the observation group was significantly lower than that in the control group. The difference was statistically significant(P<0.05). The incidence of adverse reactions in the observation group was 13.64%, compared with 23.26% in the control group, the difference was not statistically significant(χ2=1.341,P=0.247). 【Conclusion】Dapagliflozin combined with metformin hydrochloride can effectively reduce the levels of blood glucose and inflammatory factors, improve the function of islet cells in the treatment of type 2 diabetes patients, and it is safe and worthy of clinical application.
|
|
Received: 26 January 2024
|
|
|
|
|
|
[1] 刘亚琴,连明珠,赵淑杰. 2型糖尿病患者脂质比值、胰岛β细胞功能指数、超敏C反应蛋白与胰岛素抵抗的相关性研究[J].中国现代医学杂志,2023,33(17):67-75.
[2] 马林通,徐晓,王佳,等. 2型糖尿病微血管病变与血管内皮功能及血压的关系[J].山东医药,2023,63(4):67-69.
[3] 于欢,杨若彤,王斯悦,等. 2型糖尿病患者使用二甲双胍与缺血性脑卒中发病风险的队列研究[J].北京大学学报(医学版),2023,55(3):456-464.
[4] 李梅,虞泽,宋传军,等. 达格列净、沙格列汀分别联用二甲双胍对2型糖尿病患者糖脂代谢的影响[J].中国药业,2023,32(19):122-125.
[5] 赵能江,代春美,孙文杰,等.《中国2型糖尿病防治指南(2020年版)》糖尿病的中医药治疗部分解读[J].中华糖尿病杂志,2021,13(4) : 309.
[6] 杨洁,丁文萃,王海英,等. 甲状腺过氧化物酶抗体与2型糖尿病下肢血管病变的相关性研究[J].河北医科大学学报,2023,44(2):152-156.
[7] 方京徽,刘雯,张红,等. 2型糖尿病医学营养治疗临床指南执行现状定量研究分析[J].中国糖尿病杂志,2023,31(11):815-820.
[8] 廖苏丹,张弛,苏钢. 血清GLP-1、hs-CRP与2型糖尿病患者代谢综合征及认知功能的相关分析[J].河北医科大学学报,2023,44(2):157-160.
[9] 张蕊,秦诗阳,何建秋,等. 脂联素、直接胆红素及甘油三酯对2型糖尿病患者大血管病变的诊断价值[J].中国现代医学杂志,2023,33(1):13-18.
[10] 王晶,张蕊,徐琳,等. 二甲双胍对2型糖尿病患者肠道内双歧杆菌含量的影响[J].海南医学,2023,34(7):937-940.
[11] 邓丽萍,武红梅,袁唯唯. 维格列汀二甲双胍复方制剂联合达格列净治疗新诊断2型糖尿病患者的疗效及安全性观察[J].中国糖尿病杂志,2022,30(2):116-119.
[12] 郭伟,刘娜. 达格列净联合二甲双胍对2型糖尿病合并非酒精性脂肪性肝病患者肝脂肪变性的影响[J].华中科技大学学报(医学版),2023,52(4):530-534.
[13] 郑美斯,王晶璞,张淼. 达格列净联合司美格鲁肽治疗二甲双胍治疗血糖控制不佳老年2型糖尿病患者的疗效及其对胰岛功能、氧化应激反应的影响[J].临床和实验医学杂志,2023,22(14):1492-1496.
[14] 李丽莉,冯翠娟,冯克娜. 二甲双胍治疗血糖控制不佳的T2DM联合达格列净对机体糖脂指标、内脏脂肪、慢性炎症刺激的调节效应[J].河北医科大学学报,2022,43(12):1384-1389.
[15] 陈春燕,张时清,张浩,等. 达格列净联合二甲双胍对糖尿病患者的临床疗效及相关内分泌激素水平的影响[J].中国临床医生杂志,2020,48(9):1045-1047.
[16] 毛俊,曹永红,刘慧茹,等. 达格列净联合二甲双胍治疗2型糖尿病的临床研究[J].中国基层医药,2023,30(7):983-986. |
|
|
|
2024, Vol. 41 
